Q3 Earnings Beat: Lexicon Pharmaceuticals has sparked significant buzz on X following its Q3 2025 earnings report, which showed a revenue of $14.2 million, far surpassing expectations. Posts on the platform highlight the earnings beat, with adjusted EPS at $(0.04) compared to an expected $(0.07). Many are noting the impressive year-over-year revenue growth of over 700%.
Sotagliflozin Data: Discussions on X also focus on new clinical data for sotagliflozin, presented at the AHA 2025 Scientific Sessions, showing benefits for heart failure patients without diabetes. Users are intrigued by the potential impact on the company’s pipeline and future growth. The sentiment reflects curiosity about upcoming FDA feedback expected in Q4 2025.
Note: This discussion summary was generated from an AI condensation of post data.
Lexicon Pharmaceuticals Hedge Fund Activity
We have seen 49 institutional investors add shares of Lexicon Pharmaceuticals stock to their portfolio, and 80 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIREN, L.L.C. added 35,402,689 shares (+1006.8%) to their portfolio in Q2 2025, for an estimated $33,480,322
- BLACKROCK, INC. removed 6,658,338 shares (-66.5%) from their portfolio in Q2 2025, for an estimated $6,296,790
- SCHONFELD STRATEGIC ADVISORS LLC removed 3,636,841 shares (-44.3%) from their portfolio in Q2 2025, for an estimated $3,439,360
- FMR LLC added 3,594,338 shares (+10.4%) to their portfolio in Q2 2025, for an estimated $3,399,165
- SESSA CAPITAL IM, L.P. added 3,000,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $2,837,100
- STATE STREET CORP removed 1,788,953 shares (-68.6%) from their portfolio in Q2 2025, for an estimated $1,691,812
- UBS GROUP AG removed 1,694,608 shares (-80.9%) from their portfolio in Q2 2025, for an estimated $1,602,590
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Lexicon Pharmaceuticals Analyst Ratings
Wall Street analysts have issued reports on $LXRX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/02/2025
- Citigroup issued a "Buy" rating on 08/07/2025
To track analyst ratings and price targets for Lexicon Pharmaceuticals, check out Quiver Quantitative's $LXRX forecast page.
Lexicon Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $LXRX recently. We have seen 2 analysts offer price targets for $LXRX in the last 6 months, with a median target of $2.95.
Here are some recent targets:
- Joseph Pantginis from HC Wainwright & Co. set a target price of $4.0 on 09/02/2025
- Yigal Nochomovitz from Citigroup set a target price of $1.9 on 08/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
